{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:26:35Z","timestamp":1769019995407,"version":"3.49.0"},"reference-count":28,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The advent of direct-acting antivirals (DAAs) has transformed the treatment landscape of hepatitis C [...]<\/jats:p>","DOI":"10.3390\/v13081580","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T08:57:14Z","timestamp":1628585834000},"page":"1580","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["SHARED: An International Collaboration to Unravel Hepatitis C Resistance"],"prefix":"10.3390","volume":"13","author":[{"given":"Anita Y.M.","family":"Howe","sequence":"first","affiliation":[{"name":"British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Ceccherini-Silberstein","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Dietz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 1, University Hospital, Goethe University, 65926 Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Popping","sequence":"additional","affiliation":[{"name":"Erasmus Medical Center, 3015 CN Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Grebely","sequence":"additional","affiliation":[{"name":"The Kirby Institute, UNSW Sydney, Sydney, NSW 2006, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaturaka","family":"Rodrigo","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of New South Wales, Sydney, NSW 2006, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Lennerstrand","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Clinical Microbiology, Uppsala University, 75121 Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4621-3485","authenticated-orcid":false,"given":"Mark W.","family":"Douglas","sequence":"additional","affiliation":[{"name":"Storr Liver Centre, The Westmead Institute for Medical Research, The University of Sydney at Westmead Hospital, Westmead, NSW 2145, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1869-1084","authenticated-orcid":false,"given":"Milosz","family":"Parczewsk","sequence":"additional","affiliation":[{"name":"Department of Infectious Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, 70-507 Szczecin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. Richard","family":"Harrigan","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia, Vancouver, BC V5Z 4R4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0745-7559","authenticated-orcid":false,"given":"Jean-Michel","family":"Pawlotsky","sequence":"additional","affiliation":[{"name":"National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Henri Mondor Hospital & INSERM U955, 94000 Cr\u00e9teil, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7611-781X","authenticated-orcid":false,"given":"Federico","family":"Garcia","sequence":"additional","affiliation":[{"name":"Microbiology Department, University Hospital San Cecilio, Instituto de Investigacion Ibs.Granada, 18012 Granada, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHARED","family":"Collaborators","sequence":"additional","affiliation":[{"name":"British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): A single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_3","unstructured":"World Health Organization (2016). Towards the elimination of hepatitis B and C by 2030. The Draft WHO Global Hepatitis Strategy, World Health Organization."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"20310","DOI":"10.1038\/srep20310","article-title":"Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): Mining the GenBank HCV genome data","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S270","DOI":"10.1016\/S0168-8278(15)30168-9","article-title":"A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive and-experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1","volume":"62","author":"Kwo","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jhep.2021.03.004","article-title":"Treatment failure with DAA therapy: Importance of resistance","volume":"74","author":"Sarrazin","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_8","unstructured":"World Health Organization (2021). Interim Guidance for Country Validation of Viral Hepatitis Elimination. June, 2021, World Health Organization."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1093\/cid\/ciaa145","article-title":"Transmission of NS5A-Inhibitor Resistance-Associated Substitutions Among Men Who Have Sex With Men Recently Infected with Hepatitis C Virus Genotype 1a","volume":"71","author":"Popping","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection","volume":"373","author":"Foster","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.28473","article-title":"Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)","volume":"63","author":"Leroy","year":"2016","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.1016\/S0168-8278(15)30013-1","article-title":"O006: C-swift: Grazoprevir\/elbasvir+ sofosbuvir in cirrhotic and noncirrhotic, treatment-naive patients with hepatitis C virus genotype 1 infection, for durations of 4, 6 or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks","volume":"62","author":"Poordad","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1086\/505356","article-title":"Rationale and uses of a public HIV drug-resistance database","volume":"194","author":"Shafer","year":"2006","journal-title":"J. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jhep.2019.07.025","article-title":"Suboptimal SVR rates in African patients with atypical Genotype 1 subtypes: Implications for global elimination of Hepatitis, C","volume":"71","author":"Childs","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2468-1253(18)30382-0","article-title":"Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir\u2013sofosbuvir (SHARED): A single-arm trial","volume":"4","author":"Gupta","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"ofab006","DOI":"10.1093\/ofid\/ofab006","article-title":"Direct-Acting Antiviral Treatment for Hepatitis C Genotypes Uncommon in High-Income Countries: A Dutch Nationwide Cohort Study","volume":"8","author":"Isfordink","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S2468-1253(18)30343-1","article-title":"Sofosbuvir\u2013velpatasvir for treatment of chronic hepatitis C virus infection in Asia: A single-arm, open-label, phase 3 trial","volume":"4","author":"Wei","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jhep.2019.09.021","article-title":"DAA failures in African patients with \u201cunusual\u201d HCV subtypes: Hey! Didn\u2019t you know there was another world?","volume":"71","author":"Pawlotsky","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jhep.2020.05.029","article-title":"Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia","volume":"73","author":"Nguyen","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_21","first-page":"179","article-title":"The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C","volume":"4","author":"Popping","year":"2018","journal-title":"Elsevier"},{"key":"ref_22","first-page":"128A","article-title":"A real world resistance profile of virologic failures collected from an international collaboration (SHARED)","volume":"68","author":"Howe","year":"2018","journal-title":"Hepatology"},{"key":"ref_23","first-page":"77","article-title":"The Global prevalence of resistance associated substitutions (RASs) in unusual HCV subtypes","volume":"70","author":"Popping","year":"2019","journal-title":"Hepatology"},{"key":"ref_24","unstructured":"Popping, S., Fourati, S., Howe, A., Maio, V.C.D., Salazar, A.D., Rodrigo, C., Kjellin, M., Lennerstrand, J., Douglas, M., and Silberstein, F.C. (2020, January 8\u201311). Resistance-Associated Substitutions (RAS) in \u201cUnusual\u201d HCV Subtypes (#563). Proceedings of the Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA."},{"key":"ref_25","first-page":"180A","article-title":"HCV resistance patterns in a worldwide network of cohorts of GT-3a infected patients","volume":"70","author":"Fourati","year":"2019","journal-title":"Hepatology"},{"key":"ref_26","first-page":"318A","article-title":"Genotype misclassification negatively impact the choice of regimens and treatment outcomes in the management of hepatitis C","volume":"70","author":"Howe","year":"2019","journal-title":"Hepatology"},{"key":"ref_27","unstructured":"Harrigan, R.P., Chulanov, V., Zhigalkina, P., Fourati, S., Pawlotsky, J.M., Salazar Ad, F.G., Jacka, B., Verich, A., Applegate, T., and Newton, E. (2019, January 22\u201324). HCV RECall-Automated Sanger Basecalling for HCV Genotyping and Sequencing For Drug Resistance Evaluation. Proceedings of the 17th European Meeting on HIV & Hepatitits, Rome, Italy."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1093\/bioinformatics\/bty407","article-title":"Nextstrain: Real-time tracking of pathogen evolution","volume":"34","author":"Hadfield","year":"2018","journal-title":"Bioinformatics"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/8\/1580\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:43:25Z","timestamp":1760165005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/8\/1580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,10]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["v13081580"],"URL":"https:\/\/doi.org\/10.3390\/v13081580","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,10]]}}}